U.S. Markets open in 4 hrs 51 mins

Fortress Biotech, Inc. (FBIO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.7700+0.1600 (+6.13%)
At close: 1:00PM EST

2.6000 -0.17 (-6.14%)
Before hours: 4:21AM EST

Sign in to post a message.
  • k
    kenneth
    where is everyone? does no one use this converstion board? like a ghosttown. if earnings are out for real today should be much higher volume at these prices. remember they beat earnings the last 4 quarters. jmho
  • k
    kenneth
    also wasn't this above 4 bucks plus not so long ago with a price target above 9? why the big drop? jmho
  • k
    kenneth
    well run by effective management. go fbio longs. jmho
  • R
    Roty
    Big news for FBIO! It's subsidiary CKPN sign a new phase of the deal with Samsung Biologics and announced starting of the production in Samsung's facility from 2021.
  • n
    n
    I’m out once I saw Roth was involved. I’ll stick with AIM,AYTU, and EVFM.
  • R
    Roty
    Very interesting observation fron HCW analyst... 'bizarre decision' from FDA... 'opioid stack no possible on trial because all subjects respond very well from 50mg dose'... also the issue is applying for every opioid already approved by FDA.... hypothesis advanced was'political pressure '!
  • L
    L.R.
    We need a good dose of good news to turn this stock around.
  • R
    Regino
    Do you know when they release the earnings?
  • R
    Roty
    Analysts in India review on Cipla-new partial owner of ATXI and future solely owner. After ATXI CC they put on table the 2 options of Cipla 1)to Black Box IV Tramadol and remove the drug for acute pain use and compensate with use in hospitals in Nigeria and South Africa... along with negotiations to pay less for remaining shares of ATXI or 2)additional data generation to respond CRL that may take 3 months to show no staking opioid... scenario in which ATXI shareholders will receive the signed price of 13.93/share in Aprin 2021.
  • A
    Alex
    With the PDUFA meeting this weekend the shares should go above the $5 threshold. We should start to see institutional investors coming in at that point... Future looks good for this company.
  • T
    Tal
    What just happened? 36% drop?
    Bullish
  • B
    Ben
    Why is the stock still falling so much yet Avenue is having a green day? Anyone have any reasoning
  • u
    ukwildcat7
    PDUFA dates for biotech stocks. Advisory Committee Meeting calendar dates also included. The PDUFA date refers to the date the Food and Drug Administration (FDA) are expected to deliver their decision whether or not a approve a companies New Drug Application (NDA) or Biologics License Application (BLA).

    On the PDUFA date the FDA will either:

    - issue approval for marketing.

    - issue a Complete Response Letter (CRL) - i.e. rejection letter.

    Note that most large cap companies do NOT announce PDUFA dates.

    Advisory Committee Meetings

    An advisory committee provides a forum for public discussion of certain issues regarding the efficacy and/or safety of the drug. The committee will generally vote on the efficacy and safety of the product. The FDA, while not bound by the committee decision, tend to generally ( but not always ) follow the advice given by the committee when making its decision on or before the PDUFA date. An Advisory Committee meeting is generally convened approximately 2-4 months prior to the PDUFA date.

    PDUFA dates and Advisory Committee Meeting dates may also be viewed on the BioPharmCatalyst FDA Calendar.

    Blessings
    UK
    Bullish
  • S
    SKN
    An Innovative Biopharmaceutical Company Building a Diversified Pipeline of Revenue-Generating Pharmaceutical Products and Development-Stage Product Candidates
  • u
    ukwildcat7
    Fortress Biotech (NASDAQ:FBIO) Rating Increased to Buy at Zacks Investment Research
    Posted by Michael Walen on Oct 9th, 2020
  • B
    Bloodmoon
    FBIO
    has 9 drugs on the FDA CALENDAR .
    In various stages.
    buy the dips.
  • T
    Tal
    I’m buying the dip, in the next few month it will double
  • B
    Bigdog
    This will raise Monday after FDA approval
  • R
    Roty
    This is the big gain investing in FBIO-a very well structured biotech holding that keep somehow it's value even in adverse conditions(dissapointing temporar outcome of one subsidiary). Let 's remember that FBIO sold to Cipla a good stake in ATXI leveraging down a bad outcome.
  • D
    Dave
    Doubled down at 2.91. Fine price for a solid company.